Back to Sectors

NNVC

NANOVIRICIDES, INC.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 80% | 5/15/2026 | regulatory actionNEUTRAL | 60% | 5/15/2026 | capital raiseBULLISH | 40% | 5/15/2026 | margin expansionBEARISH | 70% | 5/15/2026 | dilution riskBULLISH | 80% | 5/15/2026 | regulatory actionNEUTRAL | 60% | 5/15/2026 | capital raiseBULLISH | 40% | 5/15/2026 | margin expansionBEARISH | 70% | 5/15/2026 | dilution riskMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 15

FDA granted Orphan Drug Designation for NV-387 for Measles treatment.

regulatory action
80%
neutralMay 15

Raised $7.3M through ATM and Registered Direct offerings to extend runway.

capital raise
60%
bullishMay 15

Net loss decreased from $7.37M to $6.0M over the nine-month period.

margin expansion
40%
bearishMay 15

Significant common stock issuance and contingent Series A preferred stock conversion risk.

dilution risk
70%
bullishMay 15

FDA granted Orphan Drug Designation for NV-387 for Measles treatment.

regulatory action
80%
neutralMay 15

Raised $7.3M through ATM and Registered Direct offerings to extend runway.

capital raise
60%
bullishMay 15

Net loss decreased from $7.37M to $6.0M over the nine-month period.

margin expansion
40%
bearishMay 15

Significant common stock issuance and contingent Series A preferred stock conversion risk.

dilution risk
70%

Filing History

10-QMay 15, 2026

The latest 10-Q reveals a company at a critical inflection point, balancing an innovative, broad-spectrum antiviral platform against severe capital constraints. The successful attainment of the Measles Orphan Drug Designation validates the strategic pivot toward rare diseases, providing a tangible milestone that could attract non-dilutive funding. However, the financial statements highlight a persistent struggle with liquidity, where the gap between current assets and operating requirements remains a primary concern for investors. Ultimately, the investment thesis for NanoViricides now hinges on the speed of its clinical execution. If the upcoming Phase II readouts for MPox and the proposed respiratory trials in India deliver declarative efficacy data, the company may successfully transition from a speculative biotech to a viable biodefense asset. Until then, the tension between its ambitious pipeline and its fragile balance sheet will likely drive significant volatility in the stock's valuation.